GCL
EUCRU

Glazer Capital LLC’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Glazer Capital LLC’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,502
Closed -$85K – 614
2022
Q3 		$85K Buy
8,502
+2,800
+49% +$27.9K ﹤0.01% 564
2022
Q2 		$56K Buy
5,702
+2,692
+89% +$26.7K ﹤0.01% 572
2022
Q1 		$30K Buy
+3,010
New +$29.9K ﹤0.01% 468
2021
Q4 		– Sell
-79,779
Closed -$791K – 974
2021
Q3 		$791K Hold
79,779
– – 0.01% 492
2021
Q2 		$814K Sell
79,779
-2,600
-3% -$26.1K 0.01% 538
2021
Q1 		$829K Sell
82,379
-143,306
-63% -$1.53M 0.01% 530
2020
Q4 		$2.41M Buy
+225,685
New +$2.29M 0.09% 205

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $10.3B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $6.41B AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $17.8B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return